#DrugApproval

The integration of artificial intelligence (AI) into the U.S. Food and Drug Administration’s (FDA) drug approval process would allow new medications to be approved “very, very quickly,” according to a recent statement made by a prominent U.S. presidential candidate. The assertion, made at a high-profile live event, has ignited renewed debate about the potential of AI to revolutionize pharmaceutical regulation—raising questions of safety, ethics, and global implications, including for Thailand’s own drug approval landscape.

The US Food and Drug Administration (FDA) is engaging in active discussions with technology company OpenAI as part of a broader push to modernize drug evaluation with artificial intelligence. According to recent reporting by Wired, such collaboration could mark a pivotal shift in how new medicines are reviewed—potentially reducing the time it takes to bring life-saving drugs to market, and setting global trends that are closely watched in Thailand and across Asia Wired.